Cipla has received a communication from the USFDA that the classification of Company's Goa manufacturing facility continues to be as Official Action Indicated (OAI). USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved. The Company has an ongoing derisking plan in place for new product
approvals. The Company will work closely with the USFDA and is committed to address these within the stipulated time.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
